Replies to post #198964 on Biotech Values

[DewDiligence]

EGRX—Slides #5 and #18 show a new undisclosed (presumably 505b2) program to reduce the frequency of injections in a currently-approved drug generating $400M in annual US sales. (These slides also refer to the AMRI collaboration announced today.)